

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				INT'L FILING NO.		PCT/US2004/026434	
				INT'L FILING DATE		August 10, 2004	
				APPLICANT		Bacus et al.	
				GROUP			
				EXAMINER			
				ATTORNEY DOCKET NO.		PR60446USw	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	1.	WO 04/000094	12/31/2003	PCT			
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	2.	ALBANELL et al., Activated Extracellular Singnal-regulated Kinases: Association with Epidermal Growth Factor Receptor/Transforming Growth Factor α Expression in Head and Neck Squamous Carcinoma and Inhibition by Anti-Epidermal Growth Factor Receptor Treatments, <i>Cancer Research</i> 61:6500-6510 (2001).					
	3.	BROGNARD et al., Akt/Protein Kinase B is Constitutively Active in Non-Small Cell Lung Cancer cells and Promotes Cellular Survival and Resistance to Chemotherapy and Radiation, <i>Cancer Research</i> 61:3986-3997 (2001).					
	4.	CHEN et al., Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer, <i>Oncogene</i> 20:6073-6083 (2001).					
	5.	COCKERILL et al., Indazolylamino Quinazolines and Pyridopyrimidines as Inhibitors of the EGFR and C-erbB-2, <i>Bioorganic & Med. Chem Lett.</i> 11:1401-1405 (2001).					
	6.	GRANDIS et al., Lvels of TGF- α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival, <i>J. Nat. Cancer Inst.</i> 90(11):824-832 (1998).					
	7.	HOSHINO et al., Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors, <i>Oncogene</i> 18:813-822 (1999).					
	8.	JANES et al., Activation of the Ras signaling pathway in human breast cancer cells overexpressing <i>erbB-2</i> , <i>Oncogene</i> 9:3601-3608 (1994).					
	9.	RUSNAK et al., The Characterization of Novel, Dual ErbB-2/EGFR, Tyrosine Kinase Inhibitors: Potential Therapy for Cancer, <i>Cancer Research</i> 61:7196-7203 (2001).					
	10.	RUSNAK et al., The Effect of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines <i>in Vitro</i> and <i>in Vivo</i> , <i>Mol. Cancer Ther.</i> 1:85-94 (2001).					
	11.	TARI and LOPEZ-BERESTEIN, Serum predominantly activates MAPK and Akt kinases in EGFR- and ErbB2-over-expression cells, respectively, <i>Int. J. Cancer</i> 86:295-297 (2000).					
	12.	TENZER et al., The Phosphatidylinositide 3'-Kinase/Akt Survival Pathway is a Target for the anticancer and Radiosensitizing Agent PKC412, an Inhibitor of Protein Kinase C ¹ , <i>Cancer Research</i> 61:8203-8210 (2001).					
EXAMINER					DATE CONSIDERED		
/Sean Aeder/ (05/19/2008)							
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SA/